Kazia raises AU$4.5 million and launches to share purchase plan

Kazia Therapeutics Limited (ASX: KZA) announced a placement to sophisticated and professional investors and launched a Share Purchase Plan for eligible shareholders. The proceeds will drive the company’s clinical program toward numerous serious inflection points, including the final data on the paxalisib GBM AGILE study.

Placement of AU$4,500,000, includes:

• An unconditional placement of AU$2,792,572 at AU$0.11 per share.
• A conditional placement of AU$1,707,428 at AU$0.11 per share, which is subject to approval by stakeholders at an upcoming Extraordinary GM.
• The funds of the offer will provide funding for the company’s clinical trials and general working capital purposes.
• Incorporation of a Share purchase plan allows participation by qualified shareholders on the same terms.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com